Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

OTC Deregulation

The Medicines and Healthcare products Regulatory Agency has announced the deregulation of Amorolfine and Sumatriptan.

Amorolfine is a nail lacquer licensed for the treatment of mild fungal infections of the nails. The over the counter product is called Curanail®. The Pharmaceutical Journal reports and can only be sold to patients over 18 years old with distal or lateral infection affecting up to two nails. The recommended price is £18.61.

Sumatriptan is a tablet licensed for the relief of acute migraine attacks. The over the counter product is called Imigran Recovery®. The BBC report that this product is likely to be available from mid-June at a cost of £7.99 for 2 tablets.

Action: The newly deregulated status of these products is likely to raise public interest and possibly result in increased GP consultations, especially in light of the recommended prices.

Share 'OTC Deregulation' on Email Share 'OTC Deregulation' on Delicious Share 'OTC Deregulation' on Digg Share 'OTC Deregulation' on Facebook Share 'OTC Deregulation' on Google+ Share 'OTC Deregulation' on reddit Share 'OTC Deregulation' on StumbleUpon Share 'OTC Deregulation' on Twitter

atomic-wealth

No Comments to “OTC Deregulation”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,309 spam comments.

atomic-wealth
fond-illness
summer